tirzepatide effects on heart of tirzepatide, a dual GIP and GLP-1 receptor agonist, blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats New Cleveland Clinic research finds

Our deep and diverse obesity clinical pipeline is built to attempt to address critical gaps in care and meet patients where they are with optionality

GLP-1 levels correlate with disease severity

Call today for proven weight loss care and support to help you succeed with confidence!

Learn the difference between the active ingredient and the brand name in our comprehensive guide.

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

It also includes moderate consumption of fish, poultry, and dairy, while red meat and sweets are enjoyed sparingly